Dr Lal Path Labs to acquire 70% stake in SN Genelab for up to INR 199.5 Cr
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lal Path Labs board approved acquiring 70% stake in SN Genelab, a Gujarat-based genomics diagnostics firm, for up to INR 168 Cr plus earn-out capped at INR 31.5 Cr in cash. SN Gene will become a subsidiary. FY26 turnover was INR 57.96 Cr. Deal expected to close by Nov 30, 2026. Not a related-party transaction. Move strengthens Dr Lal Path's genomics expertise and advanced diagnostics portfolio.
Expands genomics diagnostics portfolio; deal size of about INR 200 Cr is moderate. SN Gene becomes subsidiary. Positive for growth narrative.